UNSPSC 51391618: Propylhexedrine hydrochloride

This classification denotes an alpha-adrenergic agonist C10H21N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 064LUN7NZ5, chemically known as (rs)-n,.alpha.-dimethyl-cyclohexylethylamine hydrochloride, but more generally known as propylhexedrine hydrochloride, which bears US NIH Compound Identifier 102541. Most nations, for tariff and trade purposes, schedule propylhexedrine hydrochloride under HS 29213099 and SITC 51453. As of Q4 2014, PROPYLHEXEDRINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity.

SMILES: CC(CC1CCCCC1)NC.CL.

UNSPSC 51391618 Propylhexedrine hydrochloride is a Commodity code that captures pharmaceutical products and drug-related supplies procured by state and local health agencies. The recent solicitations under this code reflect broader state and local demand for controlled substances, naloxone products, and pharmaceutical deactivation systems rather than propylhexedrine specifically. State and local issuing bodies — primarily county health departments and state health agencies — use this code to procure emergency response pharmaceuticals, overdose-reversal medications, and ancillary drug management systems that support community health initiatives and harm-reduction programs. The Seminole County, Florida procurement exemplifies typical scope: the county sought 1,900 units of naloxone annually through an IFB, with quarterly deliveries to a designated community health building and shipping costs bundled into vendor pricing. Vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify eligibility verification, and workers' compensation and commercial general liability insurance.

Recent activity centers on Florida and Texas, with Seminole County (Florida) issuing a competitive IFB (IFB60459723LAS) with a response deadline of July 26, 2023, and the Texas Health and Human Services Commission posting an RFI (HHS0017013) on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs. The Texas RFI signals state-level strategic interest in alternative procurement models for pharmaceutical products outside traditional pharmacy benefit manager and group purchasing organization arrangements. Contracts under this code typically carry initial two-year terms with renewal options, fixed-fee pricing structures, and potential FEMA funding with associated federal compliance requirements. The code shows limited recent activity — only two opportunities in the available record — suggesting either niche procurement demand or inconsistent code tagging by issuing bodies.